The Emerging Role of the Thrombin Receptor (PAR-1) in Melanoma Metastasis - a Possible Therapeutic Target

Melanoma remains as the deadliest form of skin cancer with limited and inefficient treatment options available for patients with metastatic disease. Within the last decade, the thrombin receptor, Protease Activated Receptor-1, has been described as an essential gene involved in the progression of human melanoma. PAR-1 is known to activate adhesive, invasive and angiogenic factors to promote melanoma metastasis. It is overexpressed not only in metastatic melanoma cell lines but is also highly expressed in metastatic lesions as compared to primary nevi and normal skin. Recently, PAR-1 has been described to regulate the gap junction protein Connexin 43 and the tumor suppressor gene Maspin to promote the metastatic melanoma phenotype. Herein, we review the role of PAR-1 in the progression of melanoma as well as utilizing PAR-1-regulated genes as potential therapeutic targets for melanoma treatment.

[1]  W. Ruf,et al.  Thrombin generation and the pathogenesis of cancer. , 2006, Seminars in thrombosis and hemostasis.

[2]  Wei Zhang,et al.  Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  M. Hendrix,et al.  Editor's Note: The Paradoxical Expression of Maspin in Ovarian Carcinoma , 2002, Clinical Cancer Research.

[4]  C. Cohen,et al.  Maspin and Mutant p53 Expression in Malignant Melanoma and Carcinoma: Use of Tissue Microarray , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  F. Rösel,et al.  Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. , 2001, Clinical biochemistry.

[6]  L. Brass,et al.  Protease activated receptors: theme and variations , 2001, Oncogene.

[7]  M. Hendrix,et al.  Biological functions of maspin , 2006, Journal of cellular physiology.

[8]  P. Silver,et al.  Therapeutic potential of retroviral RNAi vectors , 2004, Expert opinion on biological therapy.

[9]  J. Trejo,et al.  Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer , 2007, Journal of Cell Science.

[10]  D. Laird,et al.  Connexin 43 mediated gap junctional communication enhances breast tumor cell diapedesis in culture , 2005, Breast Cancer Research.

[11]  M. El-Sabban,et al.  Cytoplasmic dye transfer between metastatic tumor cells and vascular endothelium , 1991, The Journal of cell biology.

[12]  M. Herlyn,et al.  Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. , 2000, Journal of cell science.

[13]  J. Kirkwood,et al.  Interferons in melanoma. , 1996, Current opinion in oncology.

[14]  M. Hollenberg,et al.  Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. , 2005, Human pathology.

[15]  B. Pentecost,et al.  Role of thrombin receptor in breast cancer invasiveness , 1999, British Journal of Cancer.

[16]  J. Gershenwald,et al.  Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. , 2007, The Journal of investigative dermatology.

[17]  D. Matei,et al.  Tissue Transglutaminase Regulates Matrix Metalloproteinase-2 in Ovarian Cancer by Modulating cAMP-response Element-binding Protein Activity* , 2009, The Journal of Biological Chemistry.

[18]  A. Klippel,et al.  A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium , 2006, Gene Therapy.

[19]  M. Hendrix,et al.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. , 1994, Science.

[20]  S. Sheng.  The promise and challenge toward the clinical application of maspin in cancer. , 2004, Frontiers in bioscience : a journal and virtual library.

[21]  L. Ellis,et al.  Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. , 2008, Journal of the National Cancer Institute.

[22]  W. Jonat,et al.  Expression of the tumor suppressor gene Maspin in human pancreatic cancers. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  P. Lorigan,et al.  A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma , 2000, British Journal of Cancer.

[24]  Natale Cascinelli,et al.  An Evidence‐based Staging System for Cutaneous Melanoma 1 , 2004, CA: a cancer journal for clinicians.

[25]  R. Sager,et al.  The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. , 2000, Cancer research.

[26]  W. Ruf,et al.  Orchestration of coagulation protease signaling by tissue factor. , 2002, Trends in cardiovascular medicine.

[27]  M. Nedergaard,et al.  Adhesive properties of connexin hemichannels , 2008, Glia.

[28]  Yu Shen.  Advances in the development of siRNA-based therapeutics for cancer. , 2008, IDrugs : the investigational drugs journal.

[29]  P. Grabham,et al.  Cellular consequences of thrombin-receptor activation. , 1996, The Biochemical journal.

[30]  J. Heighway,et al.  Maspin – the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer – is strongly expressed in preneoplastic bronchial lesions , 2003, Oncogene.

[31]  D. Pinkel,et al.  Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. , 2007, The Journal of investigative dermatology.

[32]  Z. Hall.  Cancer , 1906, The Hospital.

[33]  K. Willecke,et al.  Connexin-43 upregulation in micrometastases and tumor vasculature and its role in tumor cell attachment to pulmonary endothelium. , 2008, BMC medicine.

[34]  Pauli Bu,et al.  Adhesion-mediated gap junctional communication between lung-metastatatic cancer cells and endothelium. , 1994 .

[35]  M. Tainsky,et al.  Loss of AP‐2 results in downregulation of c‐KIT and enhancement of melanoma tumorigenicity and metastasis , 1998, The EMBO journal.

[36]  W. Konigsberg,et al.  Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Uchida,et al.  Thrombin Inhibitor, Argatroban, Prevents Tumor Cell Migration and Bone Metastasis , 2004, Oncology.

[38]  A. Agarwal,et al.  PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.

[39]  S. Chackalamannil.  Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. , 2006, Journal of medicinal chemistry.

[40]  J. Radhi.  Malignant Melanoma Arising from Nevi, p53, p16, and Bcl-2: Expression in Benign versus Malignant Components , 1999, Journal of cutaneous medicine and surgery.

[41]  W. Jonat,et al.  Expression and regulation of tumor suppressor gene maspin in human bladder cancer. , 2004, Cancer letters.

[42]  Reuven Reich,et al.  Thrombin receptor overexpression in malignant and physiological invasion processes , 1998, Nature Medicine.

[43]  M. Bar‐eli,et al.  Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43. , 2009, Cancer research.

[44]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[45]  H. Tsao,et al.  Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. , 2008, The Journal of investigative dermatology.

[46]  P. Henklein,et al.  PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism. , 2004, Oncology research.

[47]  K. Kaplan,et al.  The binding of thrombin by fibrin. , 1979, The Journal of biological chemistry.

[48]  A. Pardee,et al.  Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  W. Bahou.  Protease-activated receptors. , 2003, Current topics in developmental biology.

[50]  M. Kohli,et al.  Thrombin receptor expression is upregulated in prostate cancer , 2006, The Prostate.

[51]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.

[52]  A. Sood,et al.  Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. , 2008, Cancer research.

[53]  M. El-Sabban,et al.  Adhesion-mediated gap junctional communication between lung-metastatatic cancer cells and endothelium. , 1994, Invasion & metastasis.

[54]  M. Bar‐eli,et al.  Loss of Activator Protein-2α Results in Overexpression of Protease-activated Receptor-1 and Correlates with the Malignant Phenotype of Human Melanoma* , 2003, Journal of Biological Chemistry.

[55]  M. Herlyn,et al.  The Role of Altered Cell–Cell Communication in Melanoma Progression , 2003, Journal of Molecular Histology.

[56]  J. Serth,et al.  Expression of the p53 and maspin protein in primary prostate cancer: Correlation with clinical features , 2001, International journal of cancer.

[57]  K. Takeshita,et al.  Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. , 1998, Blood.

[58]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[59]  Jan-Fang Cheng,et al.  Dicer, Drosha, and outcomes in patients with ovarian cancer. , 2008, The New England journal of medicine.

[60]  Qing Shao,et al.  Connexins and Gap Junctions in Mammary Gland Development and Breast Cancer Progression , 2007, Journal of Membrane Biology.

[61]  M. Atkins,et al.  High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.

[62]  B. Loggini,et al.  Immunohistochemical Study of 49 Cutaneous Melanomas: P53, PCNA, Bcl-2 Expression and Multidrug Resistance , 2001, Tumori.

[63]  S. Coughlin,et al.  Protease‐activated receptors in hemostasis, thrombosis and vascular biology , 2005, Journal of thrombosis and haemostasis : JTH.

[64]  M. Bar‐eli,et al.  Role and regulation of the thrombin receptor (PAR-1) in human melanoma , 2003, Oncogene.

[65]  D. Rigel,et al.  Malignant melanoma: Prevention, early detection, and treatment in the 21st century , 2000, CA: a cancer journal for clinicians.

[66]  A. Sood,et al.  Strategies for in vivo siRNA delivery in cancer. , 2008, Mini reviews in medicinal chemistry.

[67]  J. Whisstock,et al.  The Serpins Are an Expanding Superfamily of Structurally Similar but Functionally Diverse Proteins , 2001, The Journal of Biological Chemistry.

[68]  J. Gershenwald,et al.  Loss of AP-2 Results in Up-regulation ofMCAM/MUC18 and an Increase in Tumor Growth and Metastasis of Human Melanoma Cells* , 1998, The Journal of Biological Chemistry.

[69]  Jeffrey E Gershenwald,et al.  Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo , 2001, Oncogene.

[70]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  S. Dhanasekaran,et al.  A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. , 2002, Urology.

[72]  M. Laburthe,et al.  Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. , 2003, The American journal of pathology.

[73]  W. Ruf,et al.  Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. , 1995, Cancer Research.

[74]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Liz Y. Han,et al.  Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy , 2006, Clinical Cancer Research.

[76]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[77]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  S. Goldman,et al.  Connexin 43 Enhances the Adhesivity and Mediates the Invasion of Malignant Glioma Cells , 2002, The Journal of Neuroscience.

[79]  A. Hartmann,et al.  Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer , 2005, The Journal of pathology.

[80]  T S Edgington,et al.  Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[81]  A. Bosserhoff,et al.  Loss of maspin expression contributes to a more invasive potential in malignant melanoma. , 2007, Pigment cell research.

[82]  V. Ellis,et al.  Maspin Inhibits Cell Migration in the Absence of Protease Inhibitory Activity* , 2002, The Journal of Biological Chemistry.

[83]  M. Runge,et al.  Cloning and Identification of Regulatory Sequences of the Human Thrombin Receptor Gene* , 1996, The Journal of Biological Chemistry.

[84]  E. Appella,et al.  p53 Regulates the Expression of the Tumor Suppressor Gene Maspin* , 2000, The Journal of Biological Chemistry.

[85]  M. Bar‐eli,et al.  Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype , 2010, Proceedings of the National Academy of Sciences.

[86]  Q. Yao,et al.  Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. , 2008, Expert opinion on therapeutic targets.